Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)
NCT06422923 · View on ClinicalTrials.gov ↗
Study Summary
This is a multicenter, single arm, open label clinical trial that is designed to test the safety and preliminary efficacy of single administration inhibitory nerve cells called interneurons (NRTX-1001), into both temporal lobes of subjects with drug-resistant bilateral mesial temporal lobe epilepsy.
Conditions Studied
Interventions
- BIOLOGICAL NRTX-1001
Study Locations (17)
California
- University of Southern California Keck Hospital — Los Angeles
- UC Irvine Medical Center — Orange
- Stanford University — Palo Alto
- University of California San Diego — San Diego
- University of California San Francisco — San Francisco
North Carolina
- Atrium Health — Charlotte
- Duke University Hospital — Durham
- Wake Forest Baptist Medical Center — Winston-Salem
Arkansas
- University of Arkansas for Medical Sciences — Little Rock
Colorado
- University of Colorado Anschutz Medical Campus — Aurora
Illinois
- University of Chicago — Chicago
Iowa
- University of Iowa Health Care — Iowa City
New York
- SUNY Upstate Medical University — Syracuse
Oregon
- Oregon Health and Science University — Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2024-11-14 |
| Est. Completion | 2042-06-15 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06422923
The ClinicalTrials.gov registry entry for NCT06422923 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neurona Therapeutics, which has 33 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Epilepsy, Temporal Lobe appearing as the primary indexed condition, and to 1 intervention — of which NRTX-1001 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06422923 reports 17 study locations spanning 11 distinct geographic areas — top geographies include California, North Carolina, Arkansas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06422923 about?
NCT06422923 is a clinical study titled "A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)". This is a multicenter, single arm, open label clinical trial that is designed to test the safety and preliminary efficacy of single administration inhibitory nerve cells called interneurons (NRTX-1001), into both temporal lobes of subjects with drug-resistant bilateral mesial temporal lobe epilepsy.
What is the current status of trial NCT06422923?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2024-11-14. Estimated completion is 2042-06-15.
What conditions does trial NCT06422923 study?
This clinical trial studies the following conditions: Epilepsy, Temporal Lobe. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06422923?
The interventions under investigation include: NRTX-1001 (BIOLOGICAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06422923?
This trial is sponsored by Neurona Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06422923 being conducted?
This trial has 17 study locations across Arkansas, California, Colorado, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.